Virtus Advisers LLC Acquires Shares of 21,291 Twist Bioscience Corporation $TWST

Key Points

• Virtus Advisers LLC has acquired 21,291 shares of Twist Bioscience Corporation, valued at approximately $836,000, making it the firm's 19th largest position.
• A significant number of institutional investors, including ARK Investment Management LLC and Vanguard Group Inc., have increased their stakes in Twist Bioscience during the 1st quarter of the year.
• Twist Bioscience has received a consensus rating of "Moderate Buy" from analysts, with a target price of $49.40, despite some firms adjusting their price targets downwards.

Virtus Advisers LLC acquired a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,291 shares of the company's stock, valued at approximately $836,000. Twist Bioscience makes up 1.1% of Virtus Advisers LLC's portfolio, making the stock its 19th largest holding.

Several other large investors also recently made changes to their positions in the business. ARK Investment Management LLC increased its position in shares of Twist Bioscience by 11.5% in the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after acquiring an additional 645,730 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Twist Bioscience by 1.0% in the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after purchasing an additional 60,276 shares during the period. First Light Asset Management LLC purchased a new position in shares of Twist Bioscience in the fourth quarter valued at $56,984,000. Nuveen LLC purchased a new position in shares of Twist Bioscience in the first quarter valued at $31,960,000. Finally, American Century Companies Inc. boosted its stake in shares of Twist Bioscience by 0.9% in the first quarter. American Century Companies Inc. now owns 763,406 shares of the company's stock valued at $29,971,000 after purchasing an additional 7,054 shares during the period.

Twist Bioscience Stock Down 2.2%

Shares of NASDAQ:TWST traded down $0.60 on Thursday, reaching $26.59. 1,539,904 shares of the company's stock were exchanged, compared to its average volume of 1,946,913. Twist Bioscience Corporation has a fifty-two week low of $24.28 and a fifty-two week high of $55.33. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The business's 50-day moving average is $32.90 and its two-hundred day moving average is $35.73.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the transaction, the chief executive officer owned 645,782 shares in the company, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,250 shares of company stock worth $193,852 over the last 90 days. 3.01% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TWST shares. JPMorgan Chase & Co. decreased their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group cut their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a report on Monday, August 4th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Finally, Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.